![](https://endpts.com/wp-content/uploads/2020/04/michel-vounatsos-via-Biogen-on-Youtube-scaled.jpg)
Michel Vounatsos, Biogen CEO (via YouTube)
Biogen scores a priority review for its Alzheimer's drug aducanumab, moving one giant leap forward in its controversial quest
Biogen scored a big win at the FDA today as regulators accepted their application for the controversial Alzheimer’s drug aducanumab and gave it a priority …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.